source
- AstraZeneca and Amgen’s Tezspire shows positive results in Phase 3 eosinophilic esophagitis trialAstraZeneca and Amgen continue to co‑develop and co‑commercialize Tezspire, an anti‑inflammatory therapy already approved for asthma and chronic rhinosinusitis. The partners are preparing another F…
- FDA greenlights first oral therapy for adult dermatomyositisThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as a treatment for adults with dermatomyositis. Dermatomyositis is a rare autoimmune condition that attacks muscle…